Literature DB >> 21819700

Skewing the balance of regulatory T-cells and T-helper 17 cells in breast cancer patients.

J Wang1, D Cai, B Ma, G Wu, J Wu.   

Abstract

This study investigated the distribution of interleukin (IL)-17-producing CD4(+) T-cells (T-helper [Th17] cells) in relation to CD4(+)CD25(+)CD127(-) cells (regulatory T-cells [T(reg)]) in tumour-infiltrating lymphocytes (TILs) and peripheral blood mononuclear cells (PBMCs) from breast cancer patients. The Th17 and T(reg) cells were evaluated by flow cytometry and reported as a percentage of total CD4(+) cells. In TILs from early breast cancer patients (n = 12), the frequency of Th17 cells was significantly higher than in PBMCs (14.5 ± 7.2% versus 6.9 ± 2.1%). In TILs from patients with advanced breast cancer (n = 15), the frequency of Th17 cells was also significantly higher than that in PBMCs (9.1 ± 5.7% versus 3.2 ± 2.3%) but lower compared with early disease. The Th17/T(reg) ratio in TILs was markedly increased in early versus advanced disease. In conclusion, Th17 and T(reg) cell accumulation in the tumour microenvironment of breast cancer occurred in early disease; Th17 cell infiltration gradually decreased and T(reg) cells accumulated with disease progression.

Entities:  

Mesh:

Year:  2011        PMID: 21819700     DOI: 10.1177/147323001103900301

Source DB:  PubMed          Journal:  J Int Med Res        ISSN: 0300-0605            Impact factor:   1.671


  10 in total

1.  Correlation between circulating myeloid-derived suppressor cells and Th17 cells in esophageal cancer.

Authors:  Zhi-Jun Jiao; Jing-Jing Gao; Sheng-Hao Hua; De-Yu Chen; Wen-Hong Wang; Hui Wang; Xu-Hui Wang; Hua-Xi Xu
Journal:  World J Gastroenterol       Date:  2012-10-14       Impact factor: 5.742

2.  Immunological response in mice bearing LM3 breast tumor undergoing pulchellin treatment.

Authors:  Djamile Cordeiro de Matos; Lívia Carolina Abreu de Ribeiro; Aline Tansini; Lucas Souza Ferreira; Marisa Campos Polesi Placeres; Lucas Luis Colombo; Iracilda Zeppone Carlos
Journal:  BMC Complement Altern Med       Date:  2012-07-24       Impact factor: 3.659

Review 3.  A role for T-lymphocytes in human breast cancer and in canine mammary tumors.

Authors:  Maria Isabel Carvalho; Isabel Pires; Justina Prada; Felisbina L Queiroga
Journal:  Biomed Res Int       Date:  2014-02-02       Impact factor: 3.411

4.  Identification of Prognostic Biomarkers and Molecular Targets Among JAK Family in Breast Cancer.

Authors:  Fangteng Liu; Hengyu Wu
Journal:  J Inflamm Res       Date:  2021-01-14

5.  Mo-MDSCs are pivotal players in colorectal cancer and may be associated with tumor recurrence after surgery.

Authors:  Izabela Siemińska; Kazimierz Węglarczyk; Marta Walczak; Agata Czerwińska; Radosław Pach; Mateusz Rubinkiewicz; Antoni Szczepanik; Maciej Siedlar; Jarek Baran
Journal:  Transl Oncol       Date:  2022-01-21       Impact factor: 4.243

Review 6.  The role of Th17 cells in the pathogenesis and treatment of breast cancer.

Authors:  Vahid Karpisheh; Majid Ahmadi; Kazem Abbaszadeh-Goudarzi; Mehran Mohammadpour Saray; Asal Barshidi; Hamed Mohammadi; Mehdi Yousefi; Farhad Jadidi-Niaragh
Journal:  Cancer Cell Int       Date:  2022-03-05       Impact factor: 5.722

7.  Cancer and Autoimmune Diseases: A Tale of Two Immunological Opposites?

Authors:  Zeev Elkoshi
Journal:  Front Immunol       Date:  2022-01-25       Impact factor: 7.561

Review 8.  Vitamin D, Th17 Lymphocytes, and Breast Cancer.

Authors:  Beata Filip-Psurska; Honorata Zachary; Aleksandra Strzykalska; Joanna Wietrzyk
Journal:  Cancers (Basel)       Date:  2022-07-27       Impact factor: 6.575

Review 9.  Immune System Effects on Breast Cancer.

Authors:  Jensen N Amens; Gökhan Bahçecioglu; Pinar Zorlutuna
Journal:  Cell Mol Bioeng       Date:  2021-06-03       Impact factor: 3.337

10.  Th17/IL-17A might play a protective role in chronic lymphocytic leukemia immunity.

Authors:  Iwona Hus; Agnieszka Bojarska-Junak; Sylwia Chocholska; Waldemar Tomczak; Justyna Woś; Anna Dmoszyńska; Jacek Roliński
Journal:  PLoS One       Date:  2013-11-01       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.